ArticleScience translational medicine2022
The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants.
Registry-linked trialOpen access · bronzeAbstract read
In one paragraph
Article in Science translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06841614 (Evaluation of the Efficacy of a Post-exposure Prophylaxis), which is not on this map. Cited by 22 papers.
0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.7field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT06841614 phase3not yet recruitingnot on this mapstarted 2026, after this paper: background citation
Evaluation of the Efficacy of a Post-exposure Prophylaxis (PEP) Strategy in Contacts at High Risk of Developing Ebola Virus Disease (EVD)
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.Virology journal · 2025Trial
- VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.The New England journal of medicine · 2023Trial
- Antiviral Profiling and Cellular Activation of Carbobicyclic Nucleoside Analogues.Journal of medicinal chemistry · 2026Article
- Prodrug strategies in developing antiviral nucleoside analogs.RSC medicinal chemistry · 2026Review
- Antiviral nanomedicine: Advantages, mechanisms and advanced therapies.Bioactive materials · 2025Review
- Review
- Broad-Spectrum Antiviral Activity of the Orally Bioavailable Antiviral ATV014 Against Multiple Coronaviruses.MedComm · 2025Article
- Anti-SARS-CoV-2 prodrug ATV006 has broad-spectrum antiviral activity against human and animal coronaviruses.Acta pharmaceutica Sinica. B · 2025Article
- Emerging Strategies and Progress in the Medical Management of Marburg Virus Disease.Pathogens (Basel, Switzerland) · 2025Review
- SARS-CoV-2 drug resistance and therapeutic approaches.Heliyon · 2025Review
- Antiviral drug recognition and elevator-type transport motions of CNT3.Nature chemical biology · 2024Article
- Drug repurposing screens identify Tubercidin as a potent antiviral agent against porcine nidovirus infections.Virus research · 2024Article
- Synthesis and Antiviral Activity of Novel β-D-N4-Hydroxycytidine Ester Prodrugs as Potential Compounds for the Treatment of SARS-CoV-2 and Other Human Coronaviruses.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Enhanced broad spectrum in vitro antiviral efficacy of 3-F-4-MeO-Bn, 3-CN, and 4-CN derivatives of lipid remdesivir nucleoside monophosphate prodrugs.Antiviral research · 2023Article
- Discovery of GS-5245 (Obeldesivir), an Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys.Journal of medicinal chemistry · 2023Article
- Anti-Coronaviral Nanocluster Restrain Infections of SARS-CoV-2 and Associated Mutants through Virucidal Inhibition and 3CL Protease Inactivation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014: an oral cyclohexanecarboxylate prodrug of 1'-CN-4-aza-7,9-dideazaadenosine C-nucleoside.Signal transduction and targeted therapy · 2023Article
- Efficacy and safety of molnupiravir in patients with Omicron variant vaccine breakthrough COVID-19 infection: a randomized, controlled trial.Frontiers in pharmacology · 2023Article
- Gossypol Broadly Inhibits Coronaviruses by Targeting RNA-Dependent RNA Polymerases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Infectivity of SARS-CoV-2 and protection against reinfection in rats.Zoological research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 7 institutions in 3 countries.
Liu CaoCentre for Infection and Immunity Studies (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, Guangdong, China.ORCID 0000-0001-7960-9414
Yingjun LiShenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis, Department of Chemistry, College of Science, Academy for Advanced Interdisciplinary Studies, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China.ORCID 0000-0002-8376-1811
Sidi YangCentre for Infection and Immunity Studies (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, Guangdong, China.ORCID 0000-0003-0251-0162
Guanguan LiShenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis, Department of Chemistry, College of Science, Academy for Advanced Interdisciplinary Studies, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China.ORCID 0000-0002-2284-0348
Qifan ZhouShenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis, Department of Chemistry, College of Science, Academy for Advanced Interdisciplinary Studies, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China.ORCID 0000-0002-5738-3511
Jing SunState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510182, Guangdong, China.ORCID 0000-0002-5543-803X
Tiefeng XuCentre for Infection and Immunity Studies (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, Guangdong, China.
Yang YangShenzhen Key Laboratory of Pathogen and Immunity, National Clinical Research Center for infectious disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen 518112, Guangdong, China.
Ruyan LiaoGuangzhou Customs District Technology Center, Guangzhou 510623, Guangdong, China.
Yongxia ShiGuangzhou Customs District Technology Center, Guangzhou 510623, Guangdong, China.
Yujian YangShenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis, Department of Chemistry, College of Science, Academy for Advanced Interdisciplinary Studies, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China.
Tiaozhen ZhuShenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis, Department of Chemistry, College of Science, Academy for Advanced Interdisciplinary Studies, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China.
Siyao HuangCentre for Infection and Immunity Studies (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, Guangdong, China.
Yanxi JiCentre for Infection and Immunity Studies (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, Guangdong, China.
Feng CongGuangdong Province Key Laboratory of Laboratory Animals, Guangdong Laboratory Animals Monitoring Institute, Guangzhou 510663, Guangdong, China.
Yinzhu LuoGuangdong Province Key Laboratory of Laboratory Animals, Guangdong Laboratory Animals Monitoring Institute, Guangzhou 510663, Guangdong, China.ORCID 0000-0002-1155-6747
Yujun ZhuGuangdong Province Key Laboratory of Laboratory Animals, Guangdong Laboratory Animals Monitoring Institute, Guangzhou 510663, Guangdong, China.ORCID 0000-0001-6229-310X
Hemi LuanSchool of Medicine, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China.ORCID 0000-0002-3807-2363
Huan ZhangCenter for Disease Control and Prevention of Guangdong Province, Guangzhou 511430, Guangdong, China.
Jingdiao ChenCenter for Disease Control and Prevention of Guangdong Province, Guangzhou 511430, Guangdong, China.
Xue LiuCentre for Infection and Immunity Studies (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, Guangdong, China.ORCID 0000-0001-9195-5408
Renru LuoCentre for Infection and Immunity Studies (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, Guangdong, China.
Lihong LiuCentre for Infection and Immunity Studies (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, Guangdong, China.
Ping WangMedi-X Pingshan, Southern University of Science and Technology, Shenzhen 518118, Guangdong, China.
Yang YuShenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis, Department of Chemistry, College of Science, Academy for Advanced Interdisciplinary Studies, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China.
Fan XingCentre for Infection and Immunity Studies (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, Guangdong, China.ORCID 0000-0001-7278-2513
Bixia KeCenter for Disease Control and Prevention of Guangdong Province, Guangzhou 511430, Guangdong, China.
Huanying ZhengCenter for Disease Control and Prevention of Guangdong Province, Guangzhou 511430, Guangdong, China.ORCID 0000-0002-2928-548X
Xiaoling DengCenter for Disease Control and Prevention of Guangdong Province, Guangzhou 511430, Guangdong, China.
Wenyong ZhangSchool of Medicine, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China.
Chuwen LinCentre for Infection and Immunity Studies (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, Guangdong, China.
Mang ShiCentre for Infection and Immunity Studies (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, Guangdong, China.ORCID 0000-0002-6154-4437
Chun-Mei LiCentre for Infection and Immunity Studies (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, Guangdong, China.ORCID 0000-0002-4034-978X
Yu ZhangGuangdong Province Key Laboratory of Laboratory Animals, Guangdong Laboratory Animals Monitoring Institute, Guangzhou 510663, Guangdong, China.ORCID 0000-0002-1551-5782
Lu ZhangGuangzhou Customs District Technology Center, Guangzhou 510623, Guangdong, China.
Jun DaiGuangzhou Customs District Technology Center, Guangzhou 510623, Guangdong, China.
Hongzhou LuShenzhen Key Laboratory of Pathogen and Immunity, National Clinical Research Center for infectious disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen 518112, Guangdong, China.ORCID 0000-0002-8308-5534
Jincun ZhaoState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510182, Guangdong, China.ORCID 0000-0003-2515-5589
Xumu ZhangShenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis, Department of Chemistry, College of Science, Academy for Advanced Interdisciplinary Studies, Southern University of Science and Technology, Shenzhen 518055, Guangdong, China.ORCID 0000-0001-5700-0608
Deyin GuoCentre for Infection and Immunity Studies (CIIS), School of Medicine, Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, Guangdong, China.ORCID 0000-0002-8297-0814
Institute of Infection and Immunity · CASouthern University of Science and Technology · CNGuangzhou Center for Disease Control and Prevention · CNGuangdong Laboratory Animals Monitoring Institute · CNMS Technology (United States) · USGuangzhou Experimental Station · CNFirst Affiliated Hospital of Guangzhou Medical University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus driving the ongoing coronavirus disease 2019 (COVID-19) pandemic, continues to rapidly evolve. Because of the limited efficacy of vaccination in prevention of SARS-CoV-2 transmission and continuous emergence of variants of concern (VOCs), orally bioavailable and broadly efficacious antiviral drugs are urgently needed. Previously, we showed that the parent nucleoside of remdesivir, GS-441524, has potent anti-SARS-CoV-2 activity. Here, we report that esterification of the 5'-hydroxyl moieties of GS-441524 markedly improved antiviral potency. This 5'-hydroxyl-isobutyryl prodrug, ATV006, demonstrated excellent oral bioavailability in rats and cynomolgus monkeys and exhibited potent antiviral efficacy against different SARS-CoV-2 VOCs in vitro and in three mouse models. Oral administration of ATV006 reduced viral loads and alleviated lung damage when administered prophylactically and therapeutically to K18-hACE2 mice challenged with the Delta variant of SARS-CoV-2. These data indicate that ATV006 represents a promising oral antiviral drug candidate for SARS-CoV-2.
Indexed as
COVID-19 Drug TreatmentProdrugsAdenosineAdenosine MonophosphateAnimalsAntiviral AgentsMiceRatsSARS-CoV-2((2R,3S,4R,5R)-5-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-5-cyano-3,4-dihydrox ytetrahydrofuran-2-yl)methyl isobutyrateAdenosineAdenosine MonophosphateAntiviral AgentsProdrugs
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT06841614ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.